Final answer:
Daclizumab is used to treat multiple sclerosis, while Basiliximab is used in organ transplantation to prevent rejection.
Step-by-step explanation:
Daclizumab:
Daclizumab is a monoclonal antibody used in the treatment of multiple sclerosis. It works by binding to CD25, a receptor on certain immune cells, and preventing their activation. By doing so, it helps to reduce inflammation and damage in the central nervous system. Daclizumab is administered through subcutaneous injections, typically once a month.
Basiliximab:
Basiliximab is a monoclonal antibody used in organ transplantation to prevent rejection. It works by binding to the interleukin-2 receptor on activated T lymphocytes, thereby blocking their proliferation. Basiliximab is given as an intravenous infusion, usually before and after transplantation, to help suppress the immune response and improve graft survival.